What does an oversold RSI indicate?

An RSI below 30 is typically considered oversold, indicating that the stock may be undervalued and due for a price correction upwards in the near term.

How is Gemina Laboratories Ltd. expected to perform in Q4 2025?

Analysts anticipate continued challenges, expecting a negative EPS trend due to high costs and low revenues, mirroring previous quarters' performances.

What does Meyka AI's forecast say about Gemina's future price?

Meyka AI projects that Gemina's stock could reach CAD 0.14 in a month, offering potential upside, although long-term outlooks are less certain and depend on operational improvements.

What is Gemina Laboratories Ltd.'s market cap?

As of the latest trading session, Gemina Laboratories Ltd. has a market capitalization of approximately CAD 6.13 million, reflecting its current share price.

What is Gemina Laboratories Ltd.’s focus in the healthcare sector?

Gemina specializes in biotechnology, specifically in the development of in-vitro diagnostics, including novel chemistries for pathogen detection, emphasizing its COVID test products.

CA Stocks

Gemina Laboratories Ltd. Q4 Earnings Preview: Key Metrics Expected Down

ByHuzaifa Zahoor December 29, 2025December 29, 2025

Gemina Laboratories Ltd. (CNQ:GLAB) is preparing to announce its fourth-quarter earnings today, with significant market attention due to its recent volatile stock performance. With the share price currently at CAD 0.08 and a daunting 38.46% decline in one day, investors are eagerly scrutinizing what’s on the horizon for this Vancouver-based biotechnology company.